FDA employees expressed serious reservations about the AI tool Elsa, stating it was rushed and its capabilities exaggerated by senior officials. Citing a lack of clear guidelines, staff emphasized Elsa should only be used for administrative tasks, not scientific evaluations. The tool, under development by Deloitte and based on Anthropic's Claude LLM, was created to replace fragmented AI efforts within the agency. However, existing pilot programs like CDRH-GPT are reportedly plagued with issues, highlighting the challenges of implementation and the need for caution.
The FDA staffers voiced concerns that the AI tool, Elsa, is being rashly promoted without clear guidelines or thought about its actual capabilities.
Staffers indicate that while there are lofty expectations from those promoting Elsas capabilities, it should remain limited to administrative tasks rather than scientific research.
Collection
[
|
...
]